New and Emerging Pharmacologic Therapies for Type 2 Diabetes, Dyslipidemia, and Obesity

Clinical Therapeutics

Volumn 35, Issue 1, 2013, Pages

  Taylor, James R ^a,b   Dietrich, Eric ^a,b   Powell, Jason G ^a,b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Canagliflozin; Dapagliflozin; Diabetes; Dyslipidemia; Exenatide extended release; Icosapent ethyl; Obesity

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; EXENDIN 4; HEMOGLOBIN A1C; ICOSAPENTAENOIC ACID ETHYL ESTER; INSULIN GLARGINE; IPRAGLIFLOZIN; LORCASERIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUSEOGLIFLOZIN; METFORMIN; PHENTERMINE PLUS TOPIRAMATE; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; TRIACYLGLYCEROL;

ARTHRALGIA; COMORBIDITY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSGEUSIA; DYSLIPIDEMIA; FATIGUE; HEADACHE; HUMAN; INSOMNIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; REVIEW; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG COSTS; DYSLIPIDEMIAS; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; OBESITY; TREATMENT OUTCOME;

EID: 84872371369     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.12.012     Document Type: Review

References (38)

1. Centers for Disease Control and Prevention Accessed November 1, 2012. http://www.cdc.gov.
2. Food and Drug Administration Accessed December 9, 2012. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
3. Byetta Accessed December 9, 2012. http://www.byetta.com.
4. Drucker D.J., Buse J.B., Taylor K., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label-non-inferiority study. Lancet 2008, 372:1240-1250.
5. Bergenstal R.M., Wysham C., MacConell L., et al. efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010, 376:431-439.
6. Diamant M., Gaal L.V., Stranks S., et al. Once weekly exenatide compared with insulin glargine titrated in patients with type 2 diabetes (DURATION-3): an open label randomised trial. Lancet 2012, 375:2234-2243.
7. Russell-Jones D., Cuddihy R.M., Hanefeld M., et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4). Diabetes Care 2012, 35:252-258.
8. Blevins T., Pullman J., Malloy J., et al. DURATION-5:exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011, 96:1301-1310.
9. Ferrannini E., Jimenez Ramos S., Salsali A., et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, placebo controlled, phase III trial. Diabetes Care 2012, 33:2217-2224.
10. Nauck M.A., Del Prato S., Meier J.J., et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin. Diabetes Care 2011, 34:2015-2022.
11. Bailey C.G., Gross J.L., Pieters A., et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with metformin:a randomized, double-blind, placebo-controlled trial. Lancet 2010, 375:2223-2233.
12. Strojek K., Yoon K.H., Hruba V., et al. Effect of dapagliflozin in patients with type 2 diaebetes who have inadequate glycaemic control with glimepiride:a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011, 13:928-938.
13. Rosenstock J., Vico M., Wei L., et al. Effects of dapagliflozin, an SGLT 2 inhibitor, on A1c, weight and hypoglycemia risk in patients with type 2 diabetes inadequately controlled with pioglitazone monotherapy. Diabetes Care 2012, 35:1473-1478.
14. Wilding J.P., Woo V., Soler N.G., et al. Long term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012, 156:405-415.
15. Rosenstock J., Aggarwal N., Polidori D., et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on therapy to metformin in subjects with type 2 diabetes. Diabetes Care 2012, 35:1232-1238.
16. Foote C., Perkovic V., Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res 2012, 9:117-123.
17. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes: a patient centered approach: position statement of American Diabetes Association and European Association for the Study of Diabetes. Diabetes Care 2012, 35:1364-1379.
18. Icosapent ethyl [package insert] 2012, Amarin Pharma Inc, Bedminster, NJ.
19. Bays H.E., Ballantyne C.M., Kastelein J.J., Isaacsohn J.L., Braeckman R.A., Soni P.N. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011, 108:682-690.
20. Ballantyne C.M., Bays H.E., Kastelien J.J., et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012, 110:984-992.
21. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final Report September 2002, National Institutes of Health, National Heart Lung, and Blood Institute, 2002 National Cholesterol Education Program, National Institutes of Health, Bethesda, MD, NIH publication 02-5215.
22. Goldberg A.C., Schonfeld G., Feldman E.B., et al. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study. Clin Ther 1989, 11:69-83.
23. Bays H.E., Tighe A.P., Sadovsky R., Davidson M.H. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther 2008, 6:391-409.
24. Jellinger P.S., Smith D.A., Mehta A.E., et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract 2012, 18(Suppl 1):1-78. AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis.
25. Brunzell J.D., Davidson M., Furberg C.D., et al. Lipoprotein management in patients with cardiometabolic risk: cardiometabolic risk consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008, 31(4):811-822.
26. Fletcher B., Berra K., Ades P., et al. Managing abnormal blood lipids: a collaborative approach: cosponsored by the Councils on Cardiovascular Nursing; Arteriosclerosis, Thrombosis, and Vascular Biology; Basic Cardiovascular Sciences; Cardiovascular Disease in the Young; Clinical Cardiology; Epidemiology and Prevention; Nutrition, Physical Activity, and Metabolism; and Stroke; and the Preventive Cardiovascular Nurses Association. Circulation 2005, 112:3184-3209.
27. Bilinnski S. A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin Accessed November 6, 2012. http://clinicaltrial.gov/ct2/results?term=hypertriglyceridemia&recr=Open.
28. Belviq (lorcaserin hydrochloride) package insert June 2012, Arena Pharmaceuticals GmbH, Zofingen, Switzerland.
29. Fidler M.C., Sanchez M., Raether B., et al. A one-year randomized trial of lorcaserin for weight-loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011, 96:3067-3077.
30. Smith S.R., Weissman N.J., Anderson C.M., et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010, 363:245-256.
31. O'Neil P.M., Smith S.R., Weissman N.J., et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity 2012, 20:1426-1436.
32. Weissman N.J., Tighe J.F., Gottdiener J.S., Gwynne J.T. Ann assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med 1998, 339:725-732.
33. Flinn R., Edney A. Arena's Diet Pill May Spur Renewed Race Accessed October 23, 2012. http://www.bloomberg.com/news/2012-06-28/arena-s-diet-pill-may-spur-renewed-race-from-drugmakers.html.
34. Qsymia (phentermine and topiramate extended-release) package insert July 2012, Vivus Inc, Mountain View, CA.
35. Allison D.B., Gadde K.M., Garvey W.T., et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial. Obesity 2011, 20:330-342.
36. Gadde K.M., Allison D.B., Ryan D.H., et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:1341-1352.
37. Garvey W.T., Ryan D.H., Look M., et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012, 95:297-308.
38. Schaer P.R., Kashyap S.R., Wolski K., et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012, 366:1567-1576.